药物诱导的Sweet综合征:法国药物警戒数据库病例/非病例研究
该研究在法国药物警戒数据库中开展病例/非病例研究,共识别136例Sweet综合征报告,涉及224种可疑药物,以抗菌药、抗肿瘤药和免疫抑制剂为主。中位起病时间为用药后15天,硼替佐米、阿扎胞苷、培非格司亭、硫唑嘌呤和苯达莫司汀的报告比值比最高。研究提示上述药物与Sweet综合征存在药物警戒信号,临床应警惕并上报相关病例。
要点
- 抗菌药、抗肿瘤药和免疫抑制剂是报告中最常见的可疑药物类别。
- 中位起病时间为用药后15天,范围1至1095天。
- 硼替佐米、阿扎胞苷、培非格司亭、硫唑嘌呤和苯达莫司汀的报告比值比最高。
核心结论
- 药物警戒数据库观察到集落刺激因子、免疫抑制剂、抗肿瘤药和抗生素与Sweet综合征发生之间存在信号。
- 临床医生应知晓这些药物与Sweet综合征的潜在关联,并鼓励上报任何药物诱导的Sweet综合征病例。
研究设计与样本
- 基于法国药物警戒数据库收录的「急性发热性中性粒细胞性皮肤病」报告开展病例/非病例研究。
主要发现
- 136例Sweet综合征报告中男性占50.7%,中位年龄59岁(范围15-91岁)。
- 共提及224种可疑药物,其中抗菌药占21.0%、抗肿瘤药占19.2%、免疫抑制剂占12.1%。
- 从开始用药到发生Sweet综合征的中位时间为15天(范围1-1095天)。
- 报告比值比最高的药物为硼替佐米74.04(95%CI 40.8-134.2)、阿扎胞苷72.14(95%CI 29.4-176.9)、培非格司亭67.05(95%CI 21.2-211.6)、硫唑嘌呤55.46(95%CI 34.8-88.4)和苯达莫司汀35.84(95%CI 11.4-112.8)。
临床怎么用
- 使用集落刺激因子、免疫抑制剂、抗肿瘤药或抗生素的患者出现Sweet综合征表现时,应考虑药物诱导可能。
- 临床医生应被鼓励上报任何药物诱导的Sweet综合征病例至药物警戒系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration. METHODS: To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non-case study on reports of 'acute febrile neutrophilic dermatosis' registered in the French pharmacovigilance database. Reporting odds ratio (ROR) with its 95% confidence interval were calculated. RESULTS: Amongthe 994 789 reports recorded in the database, 136 were Sweet's syndrome, of which 50.7% were men and the median age was 59 years (range 15-91). A total of 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics and 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet's syndrome was 15 days (range 1-1095). The highest RORs were observed with bortezomib (74.04 [40.8-134.2]), azacitidine (72.14 [29.4-176.9]), perfilgrastim (67.05 [21.2-211.6]), azathioprine (55.46 [34.8-88.4]) and bendamustine (35.84 [11.4-112.8]). CONCLUSIONS: Pharmacovigilance signals have been observed between the occurrence of Sweet's syndrome and colony-stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and should be encouraged to report any case of drug-induced Sweet's syndrome.
引用
- Martin S, Trenque T, Herlem E, et al. Drug-induced Sweet's syndrome: A case/non-case study in the French pharmacovigilance database. Br J Clin Pharmacol. 2023. PMID: 37555568. doi:10.1111/bcp.15873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。